EXEL vs the Top Picks average
| Pillar | EXEL | Book avg | Diff |
|---|---|---|---|
| Quality | 0.97 | 0.84 | +0.13 |
| Growth | 0.80 | 0.84 | -0.04 |
| Value | 0.53 | 0.78 | -0.26 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | +4.9% |
|---|---|
| 90-day change | +2.7% |
| Forward EPS estimate | $4.16 |
Over the last 90 days, what analysts expect EXEL to earn is drifting higher (+2.7%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Latest EXEL developments
Recent headlines from across the financial press · updated daily. Links open the source.
- NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXELMarketBeat ·
- BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXELMarketBeat ·
- Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXELMarketBeat ·
- BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold"MarketBeat ·
- BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54Benzinga ·
- BMO initiates Exelixis stock at Market Perform, cites patent cliffInvesting.com ·
Exelixis, Inc. (EXEL): score, valuation & FAQ
Exelixis, Inc. (EXEL) is a Biotechnology company that scores 74.1 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-) and D/E (B+). On valuation, EXEL sits about 42% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade.
Is EXEL a good stock to buy?
Bull Rankings scores EXEL 74.1 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-) and D/E (B+). A score is a quantitative screen of Exelixis, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does EXEL score 74.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). EXEL earns its highest marks on P/E (A-) and D/E (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is EXEL overvalued or undervalued?
Based on $54.14, EXEL sits about 42% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade. It trades at a 17.0x P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in EXEL?
The primary threat is the looming entry of next‑generation MET inhibitors that could erode CABOMETYX’s 35.3% margin; a margin decline would compress the 16.1 P/E and negate the 46.7% ROE advantage. Additionally, the company’s heavy reliance on a single product line exposes it to revenue concentration risk—if CABOMETYX faces regulatory setbacks or a patent cliff, the 9.2% revenue growth could stall, and the 0.42 beta would amplify volatility. A sudden increase in debt or a P/E climb above 20 would confirm the bear case and break the bull thesis.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.